Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction
Status:
Recruiting
Trial end date:
2022-12-17
Target enrollment:
Participant gender:
Summary
To determine whether long-term treatment with oral betablocker (BB) therapy after myocardial
infarction (MI) in patient with no heart failure reduces the composite outcome of death from
any cause, recurrent MI, unstable angina pectoris, stroke or heart failure.
Phase:
Phase 4
Details
Lead Sponsor:
Bispebjerg Hospital
Collaborators:
Aalborg University Hospital Aarhus Universitetshospital Amager Hospital Bispebjerg Frederiksberg Hospital Bornholm Hospital Central Denmark Region Danish Heart Foundation Gentofte Hospital Glostrup University Hospital, Copenhagen Herlev Hospital Holbaek Hospital Hospital of Southern Jutland Hospitalsenheden Midt Hospitalsenheden Vest Hvidovre University Hospital Naestved Hospital Nordsjaelland Hospital Nordsjaellands Hospital Nykoebing Hospital Odense University Hospital Region of Southern Denmark Region Zealand Regionshospitalet Horsens Silkeborg Sygehus Slagelse Hospital Svendborg Hospital Sydvestjysk Sygehus Sygehus Lillebaelt (Vejle and Kolding) The Capital Region of Denmark The North Denmark Region The Novo Nordisk Foundation Zealand University Hospital